Michael G Heckman1, Lucia Schottlaender2, Alexandra I Soto-Ortolaza2, Nancy N Diehl2, Sruti Rayaprolu2, Kotaro Ogaki2, Shinsuke Fujioka2, Melissa E Murray2, William P Cheshire2, Ryan J Uitti2, Zbigniew K Wszolek2, Matthew J Farrer2, Anna Sailer2, Andrew B Singleton2, Patrick F Chinnery2, Michael J Keogh2, Steve M Gentleman2, Janice L Holton2, Kiely Aoife2, David M A Mann2, Safa Al-Sarraj2, Claire Troakes2, Dennis W Dickson2, Henry Houlden2, Owen A Ross2. 1. From the Section of Biostatistics (M.G.H., N.N.D.) and Departments of Neuroscience (A.I.S.-O., S.R., K.O., M.E.M., D.W.D., O.A.R.) and Neurology (S.F., W.P.C., R.J.U., Z.K.W.), Mayo Clinic, Jacksonville, FL; Department of Molecular Neuroscience (L.S., A.S., H.H.), Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK; Department of Medical Genetics (M.J.F.), University of British Columbia, Vancouver, Canada; Laboratory of Neurogenetics (A.B.S.), National Institute on Aging, Bethesda, MD; Institute of Genetic Medicine (P.F.C., M.J.K.), Newcastle University, Central Parkway, Newcastle upon Tyne; Neuropathology Unit (S.M.G.), Department of Medicine, Imperial College London; Queen Square Brain Bank for Neurological Disorders (J.L.H., K.A.), Department of Molecular Neuroscience, UCL Institute of Neurology, University College London; Clinical and Cognitive Sciences Research Group (D.M.A.M.), Institute of Brain, Behavior and Mental Health, Faculty of Medical and Human Sciences, University of Manchester, Salford Royal Hospital, Salford; and MRC London Neurodegenerative Diseases Brain Bank (S.A.-S., C.T.), King's College London, UK. heckman.michael@mayo.edu. 2. From the Section of Biostatistics (M.G.H., N.N.D.) and Departments of Neuroscience (A.I.S.-O., S.R., K.O., M.E.M., D.W.D., O.A.R.) and Neurology (S.F., W.P.C., R.J.U., Z.K.W.), Mayo Clinic, Jacksonville, FL; Department of Molecular Neuroscience (L.S., A.S., H.H.), Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK; Department of Medical Genetics (M.J.F.), University of British Columbia, Vancouver, Canada; Laboratory of Neurogenetics (A.B.S.), National Institute on Aging, Bethesda, MD; Institute of Genetic Medicine (P.F.C., M.J.K.), Newcastle University, Central Parkway, Newcastle upon Tyne; Neuropathology Unit (S.M.G.), Department of Medicine, Imperial College London; Queen Square Brain Bank for Neurological Disorders (J.L.H., K.A.), Department of Molecular Neuroscience, UCL Institute of Neurology, University College London; Clinical and Cognitive Sciences Research Group (D.M.A.M.), Institute of Brain, Behavior and Mental Health, Faculty of Medical and Human Sciences, University of Manchester, Salford Royal Hospital, Salford; and MRC London Neurodegenerative Diseases Brain Bank (S.A.-S., C.T.), King's College London, UK.
Abstract
OBJECTIVE: The aim of this study was to evaluate the association between common exonic variants in the leucine-rich repeat kinase 2 (LRRK2) gene and risk of multiple system atrophy (MSA). METHODS: One series from the United States (92 patients with pathologically confirmed MSA, 416 controls) and a second series from the United Kingdom (85 patients with pathologically confirmed MSA, 352 controls) were included in this case-control study. We supplemented these data with those of 53 patients from the United States with clinically probable or possible MSA. Seventeen common LRRK2 exonic variants were genotyped and assessed for association with MSA. RESULTS: In the combined series of 177 patients with pathologically confirmed MSA and 768 controls, there was a significant association between LRRK2 p.M2397T and MSA (odds ratio [OR] = 0.60, p = 0.002). This protective effect was observed more strongly in the US series (OR = 0.46, p = 0.0008) than the UK series (OR = 0.82, p = 0.41). We observed other noteworthy associations with MSA for p.G1624G (OR = 0.63, p = 0.006) and p.N2081D (OR = 0.15, p = 0.010). The p.G1624G-M2397T haplotype was significantly associated with MSA in the US series (p < 0.0001) and combined series (p = 0.003) but not the UK series (p = 0.67). Results were consistent when additionally including the US patients with clinical MSA, where the strongest single-variant association was again observed for p.M2397T (OR = 0.59, p = 0.0005). CONCLUSIONS: These findings provide evidence that LRRK2 exonic variants may contribute to susceptibility to MSA. Validation in other series and meta-analytic studies will be important.
OBJECTIVE: The aim of this study was to evaluate the association between common exonic variants in the leucine-rich repeat kinase 2 (LRRK2) gene and risk of multiple system atrophy (MSA). METHODS: One series from the United States (92 patients with pathologically confirmed MSA, 416 controls) and a second series from the United Kingdom (85 patients with pathologically confirmed MSA, 352 controls) were included in this case-control study. We supplemented these data with those of 53 patients from the United States with clinically probable or possible MSA. Seventeen common LRRK2 exonic variants were genotyped and assessed for association with MSA. RESULTS: In the combined series of 177 patients with pathologically confirmed MSA and 768 controls, there was a significant association between LRRK2 p.M2397T and MSA (odds ratio [OR] = 0.60, p = 0.002). This protective effect was observed more strongly in the US series (OR = 0.46, p = 0.0008) than the UK series (OR = 0.82, p = 0.41). We observed other noteworthy associations with MSA for p.G1624G (OR = 0.63, p = 0.006) and p.N2081D (OR = 0.15, p = 0.010). The p.G1624G-M2397T haplotype was significantly associated with MSA in the US series (p < 0.0001) and combined series (p = 0.003) but not the UK series (p = 0.67). Results were consistent when additionally including the US patients with clinical MSA, where the strongest single-variant association was again observed for p.M2397T (OR = 0.59, p = 0.0005). CONCLUSIONS: These findings provide evidence that LRRK2 exonic variants may contribute to susceptibility to MSA. Validation in other series and meta-analytic studies will be important.
Authors: Owen A Ross; Carles Vilariño-Güell; Zbigniew K Wszolek; Matthew J Farrer; Dennis W Dickson Journal: Ann Neurol Date: 2010-03 Impact factor: 10.422
Authors: C Vilariño-Güell; A I Soto-Ortolaza; A Rajput; D C Mash; S Papapetropoulos; R Pahwa; K E Lyons; R J Uitti; Z K Wszolek; D W Dickson; M J Farrer; O A Ross Journal: Neurology Date: 2011-02-15 Impact factor: 9.910
Authors: Owen A Ross; Alexandra I Soto-Ortolaza; Michael G Heckman; Jan O Aasly; Nadine Abahuni; Grazia Annesi; Justin A Bacon; Soraya Bardien; Maria Bozi; Alexis Brice; Laura Brighina; Christine Van Broeckhoven; Jonathan Carr; Marie-Christine Chartier-Harlin; Efthimios Dardiotis; Dennis W Dickson; Nancy N Diehl; Alexis Elbaz; Carlo Ferrarese; Alessandro Ferraris; Brian Fiske; J Mark Gibson; Rachel Gibson; Georgios M Hadjigeorgiou; Nobutaka Hattori; John P A Ioannidis; Barbara Jasinska-Myga; Beom S Jeon; Yun Joong Kim; Christine Klein; Rejko Kruger; Elli Kyratzi; Suzanne Lesage; Chin-Hsien Lin; Timothy Lynch; Demetrius M Maraganore; George D Mellick; Eugénie Mutez; Christer Nilsson; Grzegorz Opala; Sung Sup Park; Andreas Puschmann; Aldo Quattrone; Manu Sharma; Peter A Silburn; Young Ho Sohn; Leonidas Stefanis; Vera Tadic; Jessie Theuns; Hiroyuki Tomiyama; Ryan J Uitti; Enza Maria Valente; Simone van de Loo; Demetrios K Vassilatis; Carles Vilariño-Güell; Linda R White; Karin Wirdefeldt; Zbigniew K Wszolek; Ruey-Meei Wu; Matthew J Farrer Journal: Lancet Neurol Date: 2011-08-30 Impact factor: 44.182
Authors: S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet Journal: Neurology Date: 2008-08-26 Impact factor: 9.910
Authors: Sonja W Scholz; Henry Houlden; Claudia Schulte; Manu Sharma; Abi Li; Daniela Berg; Anna Melchers; Reema Paudel; J Raphael Gibbs; Javier Simon-Sanchez; Coro Paisan-Ruiz; Jose Bras; Jinhui Ding; Honglei Chen; Bryan J Traynor; Sampath Arepalli; Ryan R Zonozi; Tamas Revesz; Janice Holton; Nick Wood; Andrew Lees; Wolfgang Oertel; Ullrich Wüllner; Stefano Goldwurm; Maria Teresa Pellecchia; Thomas Illig; Olaf Riess; Hubert H Fernandez; Ramon L Rodriguez; Michael S Okun; Werner Poewe; Gregor K Wenning; John A Hardy; Andrew B Singleton; Francesca Del Sorbo; Susanne Schneider; Kailash P Bhatia; Thomas Gasser Journal: Ann Neurol Date: 2009-05 Impact factor: 10.422
Authors: Monica Sanchez-Contreras; Michael G Heckman; Pawel Tacik; Nancy Diehl; Patricia H Brown; Alexandra I Soto-Ortolaza; Elizabeth A Christopher; Ronald L Walton; Owen A Ross; Lawrence I Golbe; Neill Graff-Radford; Zbigniew K Wszolek; Dennis W Dickson; Rosa Rademakers Journal: Mov Disord Date: 2016-10-06 Impact factor: 10.338
Authors: Julie Lake; Xylena Reed; Rebekah G Langston; Mike A Nalls; Ziv Gan-Or; Mark R Cookson; Andrew B Singleton; Cornelis Blauwendraat; Hampton L Leonard Journal: Mov Disord Date: 2021-09-20 Impact factor: 9.698
Authors: Catherine Labbé; Michael G Heckman; Oswaldo Lorenzo-Betancor; Melissa E Murray; Kotaro Ogaki; Alexandra I Soto-Ortolaza; Ronald L Walton; Shinsuke Fujioka; Shunsuke Koga; Ryan J Uitti; Jay A van Gerpen; Ronald C Petersen; Neill R Graff-Radford; Steven G Younkin; Bradley F Boeve; William P Cheshire; Phillip A Low; Paola Sandroni; Elizabeth A Coon; Wolfgang Singer; Zbigniew K Wszolek; Dennis W Dickson; Owen A Ross Journal: Parkinsonism Relat Disord Date: 2016-06-16 Impact factor: 4.891